洛铂与顺铂联合吉西他滨用于晚期肺癌患者化疗的疗效比较

目的:研究洛铂与顺铂联合吉西他滨用于晚期肺癌患者化疗的临床疗效,为临床治疗提供依据。方法:选取2013年1月到2015年1月我院收治的晚期肺癌患者190例,按照随机数字表法将患者分为I组和II组,每组95例,I组给予洛铂联合吉西他滨治疗,II组给予顺铂联合吉西他滨治疗,应用欧洲癌症研究和治疗组织(EORTC)的生命质量测定量表(QLQ-C30)评价治疗前、后患者的生活质量,比较两组近期疗效、远期疗效以及不良反应。结果:两组近期疗效比较无统计学意义(P0.05);I组平均缓解期(6.33±1.82)月显著长于II组的(5.13±0.84)月,I组中位生存期为(9.95±2.31)月显著长于II组的(7.82±1.24)月,比较差异均有统计学意义(P0.05);治疗后两组QLQ-C30评分均显著提高,且I组高于II组,比较差异具有统计学意义(P0.05);I组骨髓抑制发生率显著高于II组,恶心、呕吐发生率显著低于II组,比较差异具有统计学意义(P0.05)。结论:洛铂与顺铂联合吉西他滨用于晚期肺癌患者化疗近期疗效相当,洛铂联合吉西他滨具有较好远期疗效,且能提高患者生活质量,但骨髓抑制发生率较高。

Comparison of Efficacy of Lobaplatin and Cisplatin Combined with Gemcitabine in Chemotherapy for Patients with Advanced Lung Cancer

Objective:To study the clinical efficacy of lobaplatin and cisplatin combined with gemcitabine in chemotherapy for patients with advanced lung cancer, and to provide basis for clinical treatment.Methods:Selected 190 cases of patients with advanced lung cancer who were treated in our hospital from January 2013 to January 2015, and were divided into I group and II group by the random number table method, with 95 cases of patients in each group, I group was treated with lobaplatin combined with gemcitabine, II group was treated with cisplatin combined with gemcitabine, evaluated the quality of life of patients before and after treatment by the quality of life questionnaire(QLQ-C30) of European cancer research and treatment of cancer(EORTC), and compared the short-term efficacy, long-termefficacy and adverse reactions of the two groups.Results:The short-term efficacy of two groups had no statistical significance (P>0.05); The average remission period in I group was (6.33± 1.82)months, which was significantly longer than (5.13± 0.84) months of II group, the median survival time was(9.95± 2.31) months in I group, which was significantly longer than(7.82± 1.24)months of II group, the differences were statistically significant (P<0.05); The QLQ-C30 scores of two groups after treatment were significantly improved, and the I group was higher than that of II group, the difference was statistically significant (P<0.05); The incidence of bone marrow suppression in I group was significantly higher than that in II group, the incidence of nausea and vomiting was significantly lower than that of II group, the differences were statistically significant (P<0.05).Conclusion:Lobaplatin and cisplatin combined with gemcitabine in the treatment of patients with advanced lung cancer have quite short-term efficacy, while lobaplatin combined with gemcitabine has a better long-termefficacy, and is able to improve the quality of life in patients, but the incidence of bone marrowsuppression is higher.